DashboardPortfoliosFavoritenGemeinschaftEntdeckenSuchen
NOT FOR DISTRIBUTION
Loading...
  • Bestände
  • /
  • Pharmazeutika und Biotechnologie
Vor 1m aktualisiert
EAPI logo

Euroapi S.A.ENXTPA:EAPI Aktienübersicht

Marktkapitalisierung €74.5m
Vor 1m aktualisiert
Aktienkurs
n/a
1Y-75.3%
7D-8.5%
1D-8.1%
Wert des Portfolios
​
Siehe

Euroapi S.A.

ENXTPA:EAPI Lagerbericht

Marktkapitalisierung: €74.5m

  • Unternehmensüberblick
    • Bewertung
    • Ausblick und Wachstum
    • Leistungs-Rückblick
    • Finanzlage
    • Dividende
  • Management
  • Eigentümerschaft
  • Weitere Informationen
  • Aktien-Community

Euroapi (EAPI) Aktienübersicht

Euroapi S.A. entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte für die Formulierung von Human- und Tierarzneimitteln. Mehr Details

EAPI grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung3/6
Künftiges Wachstum0/6
Vergangene Leistung0/6
Finanzielle Gesundheit5/6
Dividenden0/6

Belohnungen

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Hat keine nennenswerte Marktkapitalisierung (€75M)

Volatiler Aktienkurs in den letzten 3 Monaten im Vergleich zum French -Markt


EAPI Community Fair Values

Create Narrative

See what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

AN
AnalystConsensusTarget
35.0% unterbewertet intrinsischer Abschlag
AnalystConsensusTarget
•1mo ago

Capacity Expansion And Biotechnological Processes Will Strengthen API Supply

56
0
7
AN
AnalystLowTarget
11.4% überbewertet intrinsischer Abschlag
AnalystLowTarget
•1mo ago

Rising Regulatory And Geopolitical Risks Will Undermine API Profits

40
0
0
AN
AnalystHighTarget
54.1% unterbewertet intrinsischer Abschlag
AnalystHighTarget
•2mo ago

Green Chemistry And Domestic Sourcing Will Unlock Secular Demand

26
0
0

Top Analyst Narratives

AN
AnalystConsensusTarget
35.0% unterbewertet intrinsischer Abschlag
AnalystConsensusTarget
•1mo ago

Capacity Expansion And Biotechnological Processes Will Strengthen API Supply

56
0
7
AN
AnalystLowTarget
11.4% überbewertet intrinsischer Abschlag
AnalystLowTarget
•1mo ago

Rising Regulatory And Geopolitical Risks Will Undermine API Profits

40
0
0
AN
AnalystHighTarget
54.1% unterbewertet intrinsischer Abschlag
AnalystHighTarget
•2mo ago

Green Chemistry And Domestic Sourcing Will Unlock Secular Demand

26
0
0
View all narratives

Euroapi S.A. Wettbewerber

AB Science

Symbol: ENXTPA:AB
Market cap: €56.4m

THX Pharma Société Anonyme

Symbol: ENXTPA:ALTHX
Market cap: €47.3m

Boiron

Symbol: ENXTPA:BOI
Market cap: €366.3m

Advicenne

Symbol: ENXTPA:ALDVI
Market cap: €12.6m

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Euroapi
Historische Aktienkurse
Aktueller Aktienkurs€0.78
52-Wochen-Hoch€3.44
52-Wochen-Tief€0.78
Beta0.96
1 Monat Veränderung-20.33%
3 Monate Veränderung-36.27%
1 Jahr Veränderung-75.27%
3 Jahre Veränderung-93.48%
5 Jahre Veränderungn/a
Veränderung seit IPO-94.23%

Aktuelle Nachrichten und Updates

User avatar
Narrative-Update • Aug 18

EAPI: Reset P/E Multiple Will Continue To Restrain Future Earnings

Analysts have reduced their fair value estimate for Euroapi from €1.00 to €0.70, citing updated assumptions for discount rates, expected revenue trends, profit margins and future P/E multiples. What’s in the News for Euroapi Analysts adjusted their assumptions for Euroapi’s discount rate, which influenced the latest fair value estimate.
User avatar
Narrative-Update • Aug 04

EAPI: Reset Expectations And Lower P E Multiple Could Support Rebound

Analysts have trimmed their fair value estimate for Euroapi, with the updated €1.20 target down from €1.48. This is aligned with recent Street research that reduced the official price target to €1.70 from €2.90 on revised expectations for growth, margins and future P/E levels.
Analyseartikel • Aug 02

Euroapi S.A. (EPA:EAPI) Just Reported, And Analysts Assigned A €1.20 Price Target

Shareholders in Euroapi S.A. ( EPA:EAPI ) had a terrible week, as shares crashed 20% to €0.98 in the week since its...

Recent updates

User avatar
Narrative-Update • Aug 18

EAPI: Reset P/E Multiple Will Continue To Restrain Future Earnings

Analysts have reduced their fair value estimate for Euroapi from €1.00 to €0.70, citing updated assumptions for discount rates, expected revenue trends, profit margins and future P/E multiples. What’s in the News for Euroapi Analysts adjusted their assumptions for Euroapi’s discount rate, which influenced the latest fair value estimate.
User avatar
Narrative-Update • Aug 04

EAPI: Reset Expectations And Lower P E Multiple Could Support Rebound

Analysts have trimmed their fair value estimate for Euroapi, with the updated €1.20 target down from €1.48. This is aligned with recent Street research that reduced the official price target to €1.70 from €2.90 on revised expectations for growth, margins and future P/E levels.
Analyseartikel • Aug 02

Euroapi S.A. (EPA:EAPI) Just Reported, And Analysts Assigned A €1.20 Price Target

Shareholders in Euroapi S.A. ( EPA:EAPI ) had a terrible week, as shares crashed 20% to €0.98 in the week since its...
User avatar
Narrative-Update • Jul 14

EAPI: Execution On Efficiency Plans Could Unlock Upside Under Reset Expectations

Analysts have reduced their Euroapi price target to €1.70 from €2.90, citing updated assumptions around revenue growth, profit margins, the discount rate and future P/E expectations. Analyst Commentary Recent commentary around Euroapi has focused on how the lower €1.70 price target aligns with revised expectations for revenue, margins and valuation multiples.
User avatar
Narrative-Update • Jun 30

EAPI: Reset Expectations And Higher Future P/E Could Support Rebound

Analysts have reduced their fair value estimate for Euroapi, cutting the price target from €2.00 to about €1.48. This is broadly in line with a recent move by the Street to bring targets down toward €1.70 as they factor in weaker revenue growth expectations and revised profitability assumptions alongside a higher future P/E multiple.
User avatar
Narrative-Update • Jun 16

EAPI: Revenue Contraction And Margin Pressure Will Continue To Restrain Future Earnings

Euroapi's analyst price target has been cut by €1.20 to €1.70, as analysts point to updated expectations for revenue contraction, profit margins, and a lower future P/E multiple. Analyst Commentary on Euroapi The latest research on Euroapi highlights a more cautious stance, with a reduced price target and a Neutral rating that suggests limited conviction in a strong near term recovery.
User avatar
Narrative-Update • Jun 02

EAPI: Weaker Demand And Margin Pressure Will Drag On Future Earnings

Analysts have cut Euroapi's price target sharply, with recent revisions moving from €2.90 to a range of €1.70 and €1. This reflects more cautious assumptions on revenue trends, margins and a higher P/E multiple applied to the stock.
User avatar
Narrative-Update • May 10

EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential

Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.
User avatar
Narrative-Update • Apr 22

EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings

Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.
User avatar
Narrative-Update • Apr 08

EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds

Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.
User avatar
Narrative-Update • Mar 25

EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality

Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.
User avatar
Narrative-Update • Mar 10

EAPI: Weaker 2025 Guidance Will Pressure Margins And Future Earnings Quality

Analysts have cut their Euroapi price target from €2 to €1, reflecting updated assumptions that now factor in lower revenue growth expectations, much slimmer profit margins, and a significantly higher future P/E multiple. Analyst Commentary Recent price target revisions point to a cautious stance from bearish analysts, who appear focused on execution risks and the implications for Euroapi's valuation.
User avatar
Narrative-Update • Feb 24

EAPI: Lower 2025 Guidance And Reduced Multiple Will Shape Return Profile

Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing updated assumptions on modest revenue growth, slightly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent research points to a more cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.
User avatar
Narrative-Update • Feb 09

EAPI: Lower 2025 Outlook And Cautious Stance Will Shape Return Profile

Analysts have lowered their price target on Euroapi from €2.50 to €2, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that collectively suggest a more cautious valuation stance. Analyst Commentary Bearish analysts have recently cut their price target on Euroapi from €2.50 to €2.
User avatar
Narrative-Update • Jan 25

EAPI: Execution Risks And Lower Outlook Will Shape Future Return Profile

Narrative update Analysts have trimmed their price target on Euroapi by €0.50 to €2.00, citing updated assumptions on revenue growth, profit margins and forward P/E that keep their stance cautious on the shares. Analyst Commentary Recent research has reinforced a cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.00.
User avatar
Narrative-Update • Jan 10

EAPI: Lower Profitability Assumptions And New Partnership Will Shape Future Returns

Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing softer assumptions around revenue growth, profit margins and a higher future P/E multiple as the key drivers of the reset. Analyst Commentary Bearish analysts are signalling a cautious stance on Euroapi by aligning around a lower price target of €2, narrowed from €2.50.
User avatar
Narrative-Update • Dec 19

EAPI: Higher Discount Rate Will Outweigh Benefits From New Corticosteroid Partnership

Analysts have slightly reduced their Euroapi price target, reflecting a modest reassessment of fair value. This adjustment accounts for a higher discount rate, even as long term profit margin assumptions edge up and revenue declines appear marginally less severe.
Analyseartikel • Dec 18

Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €2.68 Euroapi's €2.40 share...
Analyseartikel • Dec 18

Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%

Euroapi S.A. ( EPA:EAPI ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
Analyseartikel • Oct 03

Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analyseartikel • Aug 02

Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates

It's been a mediocre week for Euroapi S.A. ( EPA:EAPI ) shareholders, with the stock dropping 12% to €2.79 in the week...
User avatar
Neues Narrative • Mar 31

Capacity Expansion And Efficiency Improvements Will Shape Future Success

Euroapi focuses on high-margin differentiated APIs and CDMO services to boost sustainable revenue and profit margins through strategic project expansions.
Analyseartikel • Mar 06

Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report

It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...
Analyseartikel • Oct 04

Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price

Key Insights The projected fair value for Euroapi is €2.62 based on 2 Stage Free Cash Flow to Equity Current share...
Analyseartikel • Jul 29

There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise

Euroapi S.A. ( EPA:EAPI ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...
Analyseartikel • May 24

Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Those holding Euroapi S.A. ( EPA:EAPI ) shares would be relieved that the share price has rebounded 29% in the last...
Analyseartikel • Apr 10

Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analyseartikel • Mar 03

Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding

The Euroapi S.A. ( EPA:EAPI ) share price has fared very poorly over the last month, falling by a substantial 31%. For...
Analyseartikel • Mar 02

Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

There's been a major selloff in Euroapi S.A. ( EPA:EAPI ) shares in the week since it released its yearly report, with...
Analyseartikel • Dec 21

A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €5.03 With €5.47 share price...

Aktionärsrenditen

EAPIFR PharmaceuticalsFR Markt
7D-8.5%0.7%-1.4%
1Y-75.3%-4.4%-2.4%

Rendite im Vergleich zur Industrie: EAPI unter dem Niveau der Branche French Pharmaceuticals , die im vergangenen Jahr eine Rendite von -4.4% erzielte.

Rendite vs. Markt: EAPI hinter dem Markt French zurück, der im vergangenen Jahr eine Rendite von -2.4 erzielte.

Preisvolatilität

Is EAPI's price volatile compared to industry and market?
EAPI volatility
EAPI Average Weekly Movement7.8%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement4.2%
10% most volatile stocks in FR Market8.6%
10% least volatile stocks in FR Market2.1%

Stabiler Aktienkurs: Der Aktienkurs von EAPI war in den letzten 3 Monaten im Vergleich zum French -Markt volatil.

Volatilität im Zeitverlauf: EAPIDie wöchentliche Volatilität (8%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der French Aktien.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
20202,961David Seignollewww.euroapi.com/en

Euroapi S.A. entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte, die bei der Formulierung von Human- und Tierarzneimitteln zum Einsatz kommen. Das Unternehmen bietet eine Organisation zur Auftragsentwicklung und -herstellung für verschiedene Klassen von Gezeiten, die Festphasenchemie, Partikeltechnik, mikrobielle Fermentation, Synthese kleiner Moleküle, Prostaglandine, Steroide und Hormone, Opiate und kontrollierte Substanzen sowie Lipide verwendet. Das Unternehmen bietet seine Produkte Herstellern von Pharmazeutika, Generika, Tierarzneimitteln, Konsumgütern, Nahrungsmitteln und kosmetischen Produkten, Biotechnologieunternehmen und Vertriebsunternehmen sowie Auftragsentwicklungs- und -herstellungsunternehmen an.

Euroapi S.A.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Euroapi im Vergleich zum Marktanteil des Unternehmens?
EAPI grundlegende Statistiken
Marktanteil€74.51m
Gewinn(TTM)-€324.20m
Umsatz(TTM)€794.60m
0.1x
Kurs-Umsatz-Verhältnis
-0.2x
Kurs-Gewinn-Verhältnis

Ist EAPI zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
EAPI Gewinn- und Verlustrechnung (TTM)
Einnahmen€794.60m
Kosten der Einnahmen€670.50m
Bruttogewinn€124.10m
Sonstige Ausgaben€448.30m
Gewinn-€324.20m

Zuletzt gemeldete Gewinne

Jun 30, 2026

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-3.39
Bruttomarge15.62%
Nettogewinnspanne-40.80%
Schulden/Eigenkapital-Verhältnis13.5%

Wie hat sich EAPI auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/09/20 17:04
Aktienkurs zum Tagesende2026/09/18 00:00
Gewinne2026/06/30
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
  • SEC-Formular 10-K
  • SEC-Formular 10-Q
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
  • Analysten Research Berichte
  • Blue Matrix
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
  • ICE-Marktdaten
  • SEC-Formular S-1
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
  • SEC-Formular 4
  • SEC-Formular 13D
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
  • SEC-Formular 10-K
  • SEC-Formular DEF 14A
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens
  • SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Euroapi S.A. wird von 13 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Justin Steven SmithBernstein
Patrick Andrew WoodBofA Global Research
Fynn ScherzlerDeutsche Bank

Triff überall bessere Investmententscheidungen

Zum Herunterladen scannen
App Store öffnenGoogle Play öffnen
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
Datenquellen anzeigen
Märkte
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Ideen für Investitionen
  • Unterbewertete Unternehmen
  • Dividendenstarke Unternehmen
  • Insider-Käufe
  • Kernenergie
  • Autonome Fahrzeuge
  • Künstliche Intelligenz
  • Kryptowährung und Blockchain
  • Cybersicherheit
  • Weitere Ideen
Börsengemeinschaften
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Werkzeuge und Funktionen
  • Portfolio-Tracker
  • Aktien-Screener & Alarme
  • Erzählungen & faire Werte
  • Dividenden-Rechner
Nachrichten & Entdeckungen
  • Neueste Bestandsnachrichten
  • Globale Markteinsichten
  • Der Fuchsbau
  • Ideen für Investitionen
  • Community-Erzählungen
  • Was gibt's Neues?
Simply Wall St
  • Pläne & Preisgestaltung
  • Werbung},{
  • Über uns
  • Kontakt
  • Karriere
  • Hilfe-Center
  • Lernen Sie das Investieren in Aktien
  • Partnerprogramm
  • Business & Unternehmen
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Bedingungen und Konditionen
  • Datenschutzbestimmungen
  • KI-Bedingungen
  • Leitfaden für Finanzdienstleistungen